In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 361-365

  Foleno, Barbara D ^a   Abbanat, Darren ^a   Goldschmidt, Raul M ^a,b   Flamm, Robert K ^b   Paget, Steve D ^a   Webb, Glenda C ^a   Wira, Ellyn ^a   Macielag, Mark J ^a   Bush, Karen ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Focus Bio Inova Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; RWJ 416457; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIOSTASIS; DRUG POTENCY; ENTEROCOCCUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OXAZOLIDINONES; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 33845974131     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01017-06     Document Type: Article

References (17)

1. Barbachyn, M. R., and C. W. Ford. 2003. Oxazolidinone structure-activity relationships leading to linezolid. Angew. Chemie 42:2010-2023.
2. Bush, K. 2004. Antibacterial drug discovery in the 21st century. Clin. Microbiol. Infect. 10:(Suppl. 4):10-17.
3. Bush, K. 2004. Why it is important to continue antibacterial drug discovery. ASM News 70:282-286.
4. Clark, N. M., E. Hershberger, M. J. Zervosc, and J. P. Lynch III. 2003. Antimicrobial resistance among gram-positive organisms in the intensive care unit. Curr. Opin. Crit. Care 9:403-412.
5. Colca, J. R., W. G. McDonald, D. J. Waldon, L. M. Thomasco, R. C. Gadwood, E. T. Lund, G. S. Cavey, W. R. Mathews, L. D. Adams, E. T. Cecil, J. D. Pearson, J. H. Bock, J. E. Mott, D. L. Shinabarger, L. Xiong, and A. S. Mankin. 2003. Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J. Biol. Chem. 278:21972-21979.
6. Diederen, B. M. W., and J. Kluytmans. 2006. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J. Infect. 52:157-168.
7. Drusano, G. L., W. Liu, K. Bush, M. R. Deziel, M. Drusano, and A. Louie. 2005. Pharmacodynamics (PD) of RWJ-416457, a new oxazolidinone antibiotic, in a neutropenic mouse thigh model of Staphylococcus aureus (SA) infection, abstr. F-1248, p. 196. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
8. Hammerschlag, M. R., K. K. Qumei, and P. M. Roblin. 1992. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:1573-1574.
9. Hilliard, J. J., J. Melton, J. Fernandez, S. Paget, M. Macielag, R. Goldschmidt, and K. Bush. 2005. In vivo activity of the novel oxazolidinone RWJ-416457, abstr. F-1247, p. 195-196. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
10. Klugman, K. P., and J. R. Lonks. 2005. Hidden epidemic of macrolide-resistant pneumococci. Emerg. Infect. Dis. 11:802-807.
11. Livermore, D. M. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51:(Suppl. S2)ii9-ii16.
12. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
13. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. Approved standard, 6th ed. M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
14. Paget, S. D., C. M. Boggs, B. D. Foleno, R. M. Goldschmidt, M. Weidner-Wells, E. Wira, K. Bush, and M. Macielag. 2005. Synthesis and in vitro antibacterial activity of pyrrolopyrazolyl-substituted oxazolidinones, abstr. F-1242, p. 194. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Shinabarger, D. L., K. R. Marotti, R. W. Murray, A. H. Lin, E. P. Melchior, S. M. Swaney, D. S. Dunyak, W. F. Demyan, and J. M. Buysse. 1997. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41:2132-2136.
16. Waites, K. B., L. B. Duffy, T. Schmid, D. Crabb, M. S. Pate, and G. H. Cassell. 1991. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391. Antimicrob. Agents Chemother 35:1181-1185.
17. Wilcox, M. H. 2005. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin. Pharmacother. 6:2315-2326.